AB001 (Agastiya Biotech)

AB001 is an investigational, orally administered, multi-target small-molecule anticancer candidate developed by Agastiya Biotech with Vopec Pharmaceuticals. The sponsor describes AB001 as a tumor-agnostic PD-L1 checkpoint inhibitor and degrader that also inhibits mutant KRAS through an allosteric GDP-bound conformation and modulates Wnt/β-catenin, PI3K, and MAPK signaling. It is additionally reported to target cancer stem-cell biology. Agastiya reports completed Phase I testing in advanced or metastatic solid tumors and ongoing Phase II development; FDA orphan-drug designations were announced for pancreatic cancer and acute myeloid leukemia. The mechanistic, efficacy, and safety claims are sponsor-reported and should not be interpreted as independently confirmed clinical benefit. ([agastiyabiotech.com](https://www.agastiyabiotech.com/media/vopec-pharmaceuticals-and-agastiya-biotech-announce-breakthrough-phase-1-study-results-of-small-molecule-ab001-for-multiple-metastatic-solid-tumors/))